The healthcare data analysis technology provider has raised $70m in funding that will strengthen its technology as it seeks to help healthcare providers become more efficient.

Antibody developer XO1, backed by a Johnson & Johnson-backed fund, has been acquired by another Johnson & Johnson subsidiary, Janssen Parmaceuticals.

Pfizer has co-led a second funding round for the biotechnology company, which also counts Eli Lilly and GlaxoSmithKline as backers.

Pfizer-backed Cellectis, which is developing cancer treatments, will issue 3.5 million shares and could raise about $129m.

The diabetes management platform developer has now received $27m in total funding, after raising $16m from backers including Samsung and Medtronic.

Pulmatrix, an inhaled drug developer that had raised $65m in venture funding, will be acquired by publicly-listed Ruthigen in an all-share deal.

Rob Rosenberg, an alum of Lucent Technologies and corporate spin-out specialist New Venture Partners, has joined eye test technology developer EyeNetra.